When it comes to pharmaceutical or biotech stocks, positive news with regards to any product that is in development almost always leads to a rise in the stock price. That is exactly what happened with MYOV stock this morning after Myovant Sciences Ltd (NYSE:MYOV) provided updates with regards to the Phase 3 HERO study of its product relugolix.
Big NewsThe company revealed that the product in question not only managed to meet the primary endpoint but also met six other secondary endpoints. The secondary endpoints were related to symptoms men suffer from during advanced prostate ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.